Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E26.65 EPS (ttm)0.81 Insider Own1.00% Shs Outstand296.59M Perf Week2.62%
Market Cap6.39B Forward P/E19.28 EPS next Y1.12 Insider Trans-11.88% Shs Float286.25M Perf Month3.95%
Income253.40M PEG0.77 EPS next Q0.16 Inst Own79.50% Short Float3.26% Perf Quarter-25.63%
Sales583.90M P/S10.95 EPS this Y276.40% Inst Trans-2.77% Short Ratio2.47 Perf Half Y-18.27%
Book/sh2.26 P/B9.54 EPS next Y28.65% ROA39.60% Target Price36.00 Perf Year11.71%
Cash/sh1.44 P/C14.96 EPS next 5Y34.50% ROE75.50% 52W Range18.03 - 32.50 Perf YTD-29.08%
Dividend- P/FCF44.01 EPS past 5Y20.50% ROI55.40% 52W High-33.66% Beta2.11
Dividend %- Quick Ratio6.60 Sales past 5Y57.00% Gross Margin97.00% 52W Low19.58% ATR1.03
Employees372 Current Ratio6.70 Sales Q/Q162.40% Oper. Margin44.30% RSI (14)51.79 Volatility4.13% 4.64%
OptionableYes Debt/Eq0.00 EPS Q/Q584.60% Profit Margin43.40% Rel Volume0.75 Prev Close20.93
ShortableYes LT Debt/Eq0.00 EarningsMay 02 AMC Payout0.00% Avg Volume3.78M Price21.56
Recom1.90 SMA202.60% SMA50-1.11% SMA200-16.89% Volume2,829,960 Change3.01%
May-11-18Reiterated Needham Buy $33 → $30
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
May-22-18 04:15PM  Exelixis Appoints Andrew R. Peters to Newly Created Position of Vice President, Strategy Business Wire
May-21-18 07:10AM  Wired News EU Approved Exelixis/Ipsens CABOMETYX in Europe for Intermediate - or Poor-Risk Advanced Renal Cell Carcinoma ACCESSWIRE
May-19-18 09:12AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
May-17-18 09:35AM  Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer Zacks +5.63%
08:27AM  Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More Benzinga
01:01AM  Exelixis Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma Business Wire
May-16-18 08:40AM  Are Options Traders Betting on a Big Move in Exelixis (EXEL) Stock? Zacks
May-11-18 06:58PM  Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally. Zacks +5.33%
09:30AM  Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day Zacks
08:39AM  Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter Zacks
08:39AM  Array BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher Zacks
08:16AM  3 Healthcare Stocks Growing Over 100% Motley Fool
06:00AM  Bull of the Day: Exelixis (EXEL) Zacks
May-10-18 05:00PM  This Biotech Stock Crashed On Colon Cancer Flop With Roche Investor's Business Daily -14.43%
04:32PM  Why Booking Holdings, Exelixis, and L Brands Slumped Today Motley Fool
03:33PM  Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings Zacks
03:03PM  Why Exelixis Dropped Today Motley Fool
08:47AM  5 Winning Stocks With Superb Efficiency Level Zacks
01:01AM  Exelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer Business Wire
May-09-18 08:47AM  Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss Zacks
May-08-18 04:05PM  Exelixis to Present at the Bank of America Merrill Lynch Health Care Conference on May 15, 2018 Business Wire
09:59AM  Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag Zacks
May-07-18 11:45AM  Edited Transcript of EXEL earnings conference call or presentation 2-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-04-18 04:06PM  Exelixis Reaccelerates Growth Motley Fool
May-03-18 07:03PM  Cramer's lightning round: Don't buy Monster Beverageit's... CNBC Videos +7.76%
06:49PM  Cramer's lightning round: Don't buy Monster Beverageit's running out of steam CNBC
02:55PM  Exelixis (EXEL) Q1 2018 Earnings Conference Call Transcript Motley Fool
01:58PM  Top 5 Biotech Stocks for 2018 Investopedia
08:32AM  Exelixis (EXEL) Q1 Earnings & Sales Top on Cabometyx Strength Zacks
08:31AM  Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss Benzinga
May-02-18 07:46PM  Exelixis: 1Q Earnings Snapshot Associated Press
05:01PM  Exelixis Jumps After Demolishing First-Quarter Sales, Income Views Investor's Business Daily
04:06PM  Exelixis and Invenra Enter Into Collaboration to Discover and Develop Novel Biologics to Treat Cancer Business Wire
04:05PM  Exelixis Announces First Quarter 2018 Financial Results and Provides Corporate Update Business Wire
Apr-30-18 11:05AM  Is a Beat in the Cards for Exelixis (EXEL) in Q1 Earnings? Zacks
Apr-26-18 08:00AM  Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting Business Wire
Apr-18-18 02:00PM  Why Big Biotech Stocks May Get An Earnings Boost Investopedia
Apr-17-18 07:50AM  New Research Coverage Highlights Exelixis, Verizon Communications, AT&T, Snap, Allergan plc, and QUALCOMM Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +6.23%
Apr-12-18 06:00AM  Why Exelixis' Stock Broke Down in March Motley Fool
Apr-11-18 04:05PM  Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018 Business Wire
08:52AM  Exelixis (EXEL) in Focus: Stock Moves 7.7% Higher Zacks
Apr-10-18 04:13PM  Exelixis Rebounds As Analyst Urges Investors To Buy Monday's Dip Investor's Business Daily +7.68%
08:20AM  Todays Research Reports on Trending Tickers: Exact Sciences and Exelixis ACCESSWIRE
Apr-09-18 04:05PM  Exelixis Elects Dr. Maria Freire to Its Board of Directors Business Wire -6.73%
Apr-06-18 10:03AM  Moving Average Crossover Alert: Exelixis, Inc. (EXEL) Zacks
Apr-05-18 08:30AM  Todays Research Reports on Trending Tickers: Exelixis and Galectin Therapeutics ACCESSWIRE
Apr-04-18 09:15PM  3 Top Biotech Stocks to Buy in April Motley Fool
04:32PM  Why Exelixis Will Triumph In Liver Cancer Battle With Eli Lilly Investor's Business Daily
08:34AM  Weakness Seen in Exelixis (EXEL) Estimates: Should You Stay Away? Zacks
Apr-02-18 07:40AM  Wired News Exelixis Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYX ACCESSWIRE
Mar-29-18 08:20AM  Todays Research Reports on Trending Tickers: Exelixis and Sarepta Therapeutics ACCESSWIRE
Mar-28-18 09:31AM  Why Is Exelixis (EXEL) Down 17.2% Since Its Last Earnings Report? Zacks
01:05AM  Exelixis Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX® (cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma Business Wire
Mar-26-18 09:45AM  Exelixis Cabometyx Gets Positive CHMP Opinion in Europe Zacks
Mar-23-18 02:05AM  Exelixis Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma Business Wire
Mar-15-18 08:00AM  Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma Business Wire
Mar-13-18 11:29AM  Why Exelixis Fell 14.9% in February Motley Fool
Mar-09-18 07:55AM  Edited Transcript of EXEL earnings conference call or presentation 26-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Mar-06-18 04:05PM  Exelixis Announces Webcasts of Investor Conference Presentations in March Business Wire
Feb-28-18 02:26PM  5 Biotech Stocks to Sell Amid the Latest Slaughter InvestorPlace
Feb-27-18 04:27PM  These Biotechs Diverge After Biggest Moneymakers Lag Expectations Investor's Business Daily -8.20%
04:09PM  Exelixis in Transition Motley Fool
03:49PM  Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat (revised) Zacks
09:53AM  Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down Zacks
09:16AM  Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat Zacks
Feb-26-18 09:56PM  Exelixis Inc. (EXEL) Q4 2017 Earnings Conference Call Transcript Motley Fool
08:00PM  Exelixis Announces Collaborator Daiichi Sankyos Submission of Regulatory Filing for Esaxerenone (CS-3150) in Japan Business Wire
05:12PM  Exelixis meets 4Q profit forecasts Associated Press
04:58PM  Cancer Biotech Plunges Despite Narrowly Beating Quarterly Sales Views Investor's Business Daily
04:05PM  Exelixis Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update Business Wire
01:15PM  Exelixis, Inc. to Host Earnings Call ACCESSWIRE
11:14AM  Exelixis Q4 Earnings Outlook Benzinga
10:03AM  Does Exelixis Incs (NASDAQ:EXEL) PE Ratio Warrant A Sell? Simply Wall St.
Feb-23-18 09:19AM  Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost Zacks
08:55AM  Corcept's (CORT) Earnings and Sales Meet Estimates in Q4 Zacks
Feb-22-18 08:20AM  Todays Research Reports on Trending Tickers: AVEO Pharmaceuticals and Exelixis ACCESSWIRE
Feb-21-18 08:52AM  Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again? Zacks
Feb-20-18 08:27AM  Novartis Psoriasis Drug Cosentyx Positive in SCALP Study Zacks
Feb-19-18 10:04AM  AbbVie Presents New Data on Upadacitinib for Crohn's Disease Zacks
08:43AM  Celgene Reports Positive Data on Dermatology Drug Otezla Zacks
Feb-16-18 10:16AM  Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat Zacks
08:53AM  Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion Zacks
06:08AM  Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb Motley Fool
Feb-15-18 03:01PM  Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates Zacks
08:02AM  Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva Zacks
Feb-14-18 05:55PM  Roche's Rituxan Gets Priority Review for Label Expansion Zacks
05:48PM  AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda Zacks
04:05PM  Exelixis to Present at the RBC Capital Markets Global Healthcare Conference on February 21, 2018 Business Wire
01:43PM  Exelixis Reports Positive Data From Thyroid Carcinoma Trial Zacks
11:14AM  Catalyst Gets Positive FDA Advise on Firdapse NDA Refiling Zacks
Feb-13-18 04:05PM  Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Business Wire
10:35AM  Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval Zacks
08:30AM  Todays Research Reports on Trending Tickers: Exelixis and 22nd Century Group ACCESSWIRE
08:16AM  Intercept Starts OCA Trial for NASH Patients With Cirrhosis Zacks
Feb-09-18 11:35AM  FDA Okays J&J's Prostate Cancer Drug in First-Line Setting Zacks
Feb-08-18 04:05PM  Exelixis to Release Fourth Quarter and Full Year 2017 Financial Results on Monday, February 26, 2018 Business Wire -7.13%
11:26AM  Theravance, J&J Ink Deal for Inflammatory Intestinal Drug Zacks
09:49AM  Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down Zacks
Feb-07-18 08:14AM  Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural Zacks
08:00AM  Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Genitourinary (GU) Tumors Business Wire
Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Haley Patrick J.Sr. Vice President, CommercialMay 18Sale21.613,66379,157127,278May 18 08:02 PM
SCANGOS GEORGE ADirectorMay 15Option Exercise11.6615,000174,9001,478,648May 16 07:59 PM
MARCHESI VINCENT TDirectorMay 11Option Exercise11.6615,000174,900140,913May 11 07:58 PM
MARCHESI VINCENT TDirectorMay 11Sale19.0315,000285,450125,913May 11 07:58 PM
COHEN CHARLESDirectorMay 09Option Exercise11.6615,000174,900263,180May 10 08:03 PM
COHEN CHARLESDirectorMay 09Sale21.4215,000321,300248,180May 10 08:03 PM
Haley Patrick J.Sr. Vice President, CommercialMay 07Option Exercise1.9015,00028,500145,941May 07 08:06 PM
PAPADOPOULOS STELIOSDirectorMay 07Option Exercise11.6615,000174,9001,049,314May 07 08:07 PM
PAPADOPOULOS STELIOSDirectorMay 07Sale22.1515,000332,2501,034,314May 07 08:07 PM
Haley Patrick J.Sr. Vice President, CommercialMay 07Sale22.0015,000330,000130,941May 07 08:06 PM
Haley Patrick J.Sr. Vice President, CommercialMay 04Option Exercise1.9010,00019,000143,490May 07 08:06 PM
Hessekiel JeffreyEVP and General CounselMay 04Sale22.3620,000447,200319,450May 07 08:07 PM
Haley Patrick J.Sr. Vice President, CommercialMay 04Sale22.3812,549280,847130,941May 07 08:06 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 03Option Exercise5.5022,500123,750300,788May 04 07:06 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 03Sale23.0922,500519,417278,288May 04 07:06 PM
Hessekiel JeffreyEVP and General CounselApr 27Option Exercise1.7025,00042,500339,450Apr 30 08:23 PM
Haley Patrick J.Sr. Vice President, CommercialApr 24Option Exercise1.7020,00034,000133,490Apr 26 08:22 PM
Garber Alan MDirectorApr 16Option Exercise11.6615,000174,90076,329Apr 18 08:11 PM
WYSZOMIERSKI JACK LDirectorApr 16Option Exercise9.8230,000294,450108,803Apr 18 08:12 PM
WYSZOMIERSKI JACK LDirectorApr 16Sale20.2514,959302,92093,844Apr 18 08:12 PM
Garber Alan MDirectorApr 16Sale20.2515,000303,75061,329Apr 18 08:11 PM
MORRISSEY MICHAELPresident and CEOApr 11Option Exercise5.5090,000495,000221,653Apr 13 08:09 PM
MORRISSEY MICHAELPresident and CEOApr 11Sale20.7890,0001,870,200131,653Apr 13 08:09 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOApr 06Option Exercise7.1814,591104,763277,280Apr 06 07:48 PM
MARCHESI VINCENT TDirectorMar 06Option Exercise7.9715,000119,550140,913Mar 07 07:23 PM
MARCHESI VINCENT TDirectorMar 06Sale24.7315,000370,950125,913Mar 07 07:23 PM
COHEN CHARLESDirectorMar 05Option Exercise7.9715,000119,550263,180Mar 07 07:25 PM
FELDBAUM CARL BDirectorMar 05Option Exercise11.6611,000128,26045,733Mar 07 07:26 PM
FELDBAUM CARL BDirectorMar 05Sale23.8811,000262,68034,733Mar 07 07:26 PM
COHEN CHARLESDirectorMar 05Sale24.2315,000363,450248,180Mar 07 07:25 PM
WILLSEY LANCEDirectorMar 02Option Exercise9.8230,000294,450498,273Mar 02 08:01 PM
PAPADOPOULOS STELIOSDirectorMar 02Option Exercise7.9715,000119,5501,049,314Mar 02 08:03 PM
PAPADOPOULOS STELIOSDirectorMar 02Sale24.0515,000360,7501,034,314Mar 02 08:03 PM
WILLSEY LANCEDirectorMar 02Sale23.9130,000717,300468,273Mar 02 08:01 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 01Option Exercise4.427,29332,235262,689Mar 02 08:04 PM
POSTE GEORGEDirectorFeb 28Option Exercise11.6615,000174,90098,398Mar 02 07:59 PM
Haley Patrick J.Sr. Vice President, CommercialFeb 28Option Exercise2.5813,62535,200158,519Mar 02 08:00 PM
Haley Patrick J.Sr. Vice President, CommercialFeb 28Sale27.1345,0291,221,637113,490Mar 02 08:00 PM
POSTE GEORGEDirectorFeb 28Sale26.2615,000393,90083,398Mar 02 07:59 PM
Garber Alan MDirectorJan 09Option Exercise7.9711,50091,65572,829Jan 10 07:27 PM
Garber Alan MDirectorJan 09Sale30.0011,500345,00061,329Jan 10 07:27 PM
Garber Alan MDirectorJan 08Option Exercise7.973,50027,89564,829Jan 10 07:27 PM
Garber Alan MDirectorJan 08Sale31.293,500109,51561,329Jan 10 07:27 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Option Exercise9.9133,334330,340216,339Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 28Option Exercise1.9025,00047,500292,946Sep 28 07:47 PM
Hessekiel JeffreyEVP and General CounselSep 28Sale24.3225,000608,000267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Sale23.7433,334791,349183,005Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 27Option Exercise1.902,3024,374270,248Sep 28 07:47 PM
Hessekiel JeffreyEVP and General CounselSep 27Sale23.902,30255,018267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Sale23.9433,333797,992183,005Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Sale23.6833,333789,325183,005Sep 28 07:45 PM
PAPADOPOULOS STELIOSDirectorSep 22Sale25.4010,000254,0000Sep 22 07:07 PM
PAPADOPOULOS STELIOSDirectorSep 19Sale27.63127,7903,530,8381,034,314Sep 20 06:48 PM
PAPADOPOULOS STELIOSDirectorSep 18Sale27.7672,2102,004,5501,162,104Sep 20 06:48 PM
MORRISSEY MICHAELPresident and CEOSep 14Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialSep 14Sale27.2160,6401,650,01441,553Sep 15 06:43 PM
MORRISSEY MICHAELPresident and CEOSep 14Sale27.08100,0002,708,00060,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 13Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
WILLSEY LANCEDirectorSep 13Sale26.9750,0001,348,500468,273Sep 14 07:18 PM
MORRISSEY MICHAELPresident and CEOSep 13Sale27.04100,0002,704,00060,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 12Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
Senner Christopher J.EVP and CFOSep 12Option Exercise3.66100,000366,000202,759Sep 14 07:17 PM
WILLSEY LANCEDirectorSep 12Sale26.7950,0001,339,500518,273Sep 14 07:18 PM
Senner Christopher J.EVP and CFOSep 12Sale26.79100,0002,679,000102,759Sep 14 07:17 PM
MORRISSEY MICHAELPresident and CEOSep 12Sale26.59100,0002,659,00060,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialMay 30Sale18.465,00092,300102,193Jun 01 07:09 PM